Last reviewed · How we verify
20-mg Desloratadine
20-mg Desloratadine, marketed by Organon and Co, is an established product in the antihistamine market. The key composition patent is set to expire in 2028, providing a clear period of exclusivity and potential revenue stability. The primary risk lies in the competitive landscape, which could intensify as the patent expiration approaches.
At a glance
| Generic name | 20-mg Desloratadine |
|---|---|
| Also known as | SCH 34117, Clarinex, Aerius |
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Omalizumab on Allergic Rhinitis Symptoms: a Comparative Study (PHASE4)
- Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849) (PHASE4)
- Antiplatelet Therapy in Chronic Urticaria (PHASE2)
- Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis (PHASE3)
- Comparison of Desloratadine Associated With Prednisolone (Tablet)Versus Dexchlorpheniramine Associated With Betamethasone (Tablet) for Adult Persistent Allergic Rhinitis Treatment (PHASE3)
- Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU) (PHASE3)
- A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine (PHASE3)
- Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 20-mg Desloratadine CI brief — competitive landscape report
- 20-mg Desloratadine updates RSS · CI watch RSS
- Organon and Co portfolio CI